Impact of EUS in liver transplantation workup for patients with unresectable perihilar cholangiocarcinoma

被引:3
作者
de Jong, David M. [1 ]
den Hoed, Caroline M. [1 ,2 ]
Willemssen, Francois E. J. A. [3 ]
Thomeer, Maarten G. J. [3 ]
Bruno, Marco J. [1 ]
Koerkamp, Bas Groot [4 ]
de Jonge, Jeroen [2 ,4 ]
Alwayn, Ian P. J. [5 ]
van Hooft, Jeanin E. [6 ]
Hoogwater, Frederik [7 ]
Heide, Frans van der [8 ]
Inderson, Akin [6 ]
van Vilsteren, Frederike G. I.
van Driel, Lydi M. J. W. [9 ]
机构
[1] Erasmus MC Canc Inst Univ, Dept Gastroenterol & Hepatol, Med Ctr, Rotterdam, Netherlands
[2] Erasmus MC Transplant Inst, Rotterdam, Netherlands
[3] Erasmus MC Canc Inst Univ, Dept Radiol & Nucl Med, Med Ctr, Rotterdam, Netherlands
[4] Erasmus MC Univ, Med Ctr, Dept Surg, Rotterdam, Netherlands
[5] Leiden Univ, Med Ctr, Dept Surg, Leiden, Netherlands
[6] Leiden Univ, Med Ctr, Dept Gastroenterol & Hepatol, Leiden, Netherlands
[7] Univ Groningen, Univ Med Ctr Groningen, Dept Hepatobiliary Surg & Liver Transplantat, Groningen, Netherlands
[8] Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands
[9] Erasmus MC Univ, Dept Gastroenterol & Hepatol, Med Ctr, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
关键词
ENDOSCOPIC ULTRASOUND; CHEMORADIATION; SURGERY; THERAPY; SOCIETY; FNA;
D O I
10.1016/j.gie.2023.10.047
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims: For a highly selected group of patients with unresectable perihilar cholangiocarcinoma (pCCA), liver transplantation (LT) is a treatment option. The Dutch screening protocol comprises nonregional lymph node (LN) assessment by EUS, and whenever LN metastases are identi fi ed, further LT screening is precluded. The aim of this study is to investigate the yield of EUS in patients with pCCA who are potentially eligible for LT. Methods: In this retrospective, nationwide cohort study, all consecutive patients with suspected unresectable pCCA who underwent EUS in the screening protocol for LT were included from 2011 to 2021. During EUS, sampling of a " suspicious " nonregional LN was performed based on the endoscopist ' s discretion. The primary outcome was the added value of EUS, de fi ned as the number of patients who were precluded from further screening because of malignant LNs. Results: A total of 75 patients were included in whom 84 EUS procedures were performed, with EUS-guided tissue acquisition con fi rming malignancy in LNs in 3 of 75 (4%) patients. In the 43 who underwent surgical staging according to the protocol, nonregional LNs with malignancy were identi fi ed in 6 (14%) patients. Positive regional LNs were found in 7 patients in post-LT-resected specimens. Conclusions: Our current EUS screening for the detection of malignant LNs in patients with pCCA eligible for LT shows a limited but clinically important yield. EUS with systematic screening of all LN stations, both regional and nonregional, and the sampling of suspicious lymph nodes according to de fi ned and set criteria could potentially increase this yield. (Gastrointest Endosc 2024;99:548-56.)
引用
收藏
页码:548 / 556
页数:9
相关论文
共 50 条
  • [21] Liver transplantation for hilar cholangiocarcinoma
    Robles, Ricardo
    Sanchez-Bueno, Francisco
    Ramirez, Pablo
    Brusadin, Roberto
    Parrilla, Pascual
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (48) : 9209 - 9215
  • [22] Liver transplantation for intrahepatic cholangiocarcinoma
    Lee, David D.
    Croome, Kristopher P.
    Musto, Kaitlyn R.
    Melendez, Jose
    Tranesh, Ghassan
    Nakhleh, Raouf
    Taner, C. Burcin
    Nguyen, Justin H.
    Patel, Tushar
    Harnois, Denise M.
    LIVER TRANSPLANTATION, 2018, 24 (05) : 634 - 644
  • [23] Liver Transplantation for Hilar Cholangiocarcinoma
    Sonnenday, Christopher J.
    SURGICAL CLINICS OF NORTH AMERICA, 2024, 104 (01) : 183 - 196
  • [24] Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma
    Chen, Peizhan
    Li, Bin
    Zhu, Yan
    Chen, Wei
    Liu, Xin
    Li, Mian
    Duan, Xiaohua
    Yi, Bin
    Wang, Jinghan
    Liu, Chen
    Luo, Xiangji
    Li, Xiaoguang
    Li, Jingquan
    Liang, Lijian
    Yin, Xiaoyu
    Wang, Hui
    Jiang, Xiaoqing
    ONCOTARGET, 2016, 7 (24) : 37319 - 37330
  • [25] Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma
    Matsuyama, Ryusei
    Mori, Ryutaro
    Ota, Yohei
    Homma, Yuki
    Yabusita, Yasuhiro
    Hiratani, Seigo
    Murakami, Takashi
    Sawada, Yu
    Miyake, Kentaro
    Shimizu, Yasuhiro
    Kumamoto, Takafumi
    Endo, Itaru
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (04) : 2393 - 2405
  • [26] Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma
    Murad, Sarwa Darwish
    Kim, W. Ray
    Therneau, Terry
    Gores, Gregory J.
    Rosen, Charles B.
    Martenson, James A.
    Alberts, Steven R.
    Heimbach, Julie K.
    HEPATOLOGY, 2012, 56 (03) : 972 - 981
  • [27] RADIOTHERAPY IN THE TREATMENT OF PATIENTS WITH UNRESECTABLE EXTRAHEPATIC CHOLANGIOCARCINOMA
    Ghafoori, A. Paiman
    Nelson, John W.
    Willett, Christopher G.
    Chino, Junzo
    Tyler, Douglas S.
    Hurwitz, Herbert I.
    Uronis, Hope E.
    Morse, Michael A.
    Clough, Robert W.
    Czito, Brian G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (03): : 654 - 659
  • [28] Validation study of postoperative liver failure and mortality risk scores after liver resection for perihilar cholangiocarcinoma
    Noji, Takehiro
    Uemura, Satoko
    Wiggers, Jimme K.
    Tanaka, Kimitaka
    Nakanishi, Yoshitsugu
    Asano, Toshimichi
    Nakamura, Toru
    Tsuchikawa, Takahiro
    Okamura, Keisuke
    Olthof, Pim B.
    Jarnagin, William R.
    van Gulik, Thomas M.
    Hirano, Satoshi
    HEPATOBILIARY SURGERY AND NUTRITION, 2022, 11 (03) : 375 - 385
  • [29] Clinical impact of irreversible electroporation ablation for unresectable hilar cholangiocarcinoma
    Hsiao, Chih-Yang
    Yang, Po-Chih
    Li, Xiaoyong
    Huang, Kai-Wen
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [30] Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series
    Abdelrahim, Maen
    Al-Rawi, Hadeel
    Esmail, Abdullah
    Xu, Jiaqiong
    Umoru, Godsfavour
    Ibnshamsah, Fahad
    Abudayyeh, Ala
    Victor, David
    Saharia, Ashish
    McMillan, Robert
    Al Najjar, Ebtesam
    Bugazia, Doaa
    Al-Rawi, Maryam
    Ghobrial, Rafik M.
    CURRENT ONCOLOGY, 2022, 29 (05) : 3585 - 3594